Needham & Company Maintains a 'Buy' on Vivus (VVUS); Risks Around Topiramate/Phentermine are Manageable
Tweet Send to a Friend
Needham & Company maintains a 'Buy' on Vivus (NASDAQ: VVUS).
Needham analyst says, "We continue to believe risks associated with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "We continue to believe risks associated with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
